Oncimmune : Notification & Public Disclosure of a Transaction

RNS Number : 9035V Oncimmune Holdings PLC 26 July 2018

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Oncimmune Holdings plc("Oncimmune" or the "Company")

Notification and Public Disclosure of a Transaction

No ngham, UK - 26 July 2018:Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detec3on company developing and commercialising its proprietaryEarlyCDT®liquid biopsy pla5orm technology, today announces that on 25 July 2018, share op3ons over 47,883 £0.01 ordinary shares of the Company were awarded to a consultant under the Company's USA Incentive Stock Option Plan.

Position	Number of Share Options Awarded	Exercise price per Share	Percentage of issued ordinary share capital
Consultant	47,883	£1.225	0.07%

The op3ons are subject to the USA Incen3ve Stock Op3on Plan and vest in five equal annual parts, the first fi@h ves3ng on 25 July 2019 and each year therea@er for a further four years. All these op3ons are exercisable at £1.225 pence, being the mid-market price of the Company's ordinary shares at the close of day on 25 July 2018.

For further information:

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive [e-mail]

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Giles Balleny [phone]

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson [phone]

Berenberg (Joint Broker)

Toby Flaux, Charlotte Sutcliffe [phone]

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Lindsey [e-mail][phone]

About Oncimmune

Oncimmune is a leading early cancer detec3on company developing and commercialising its proprietaryEarlyCDT®pla5orm technology. Oncimmune has pioneered the development of autoan3body tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product,EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 155,000 commercial tests have been sold.EarlyCDT®-Lungis available through physicians in the US and also privately in the UK, Europe & Asia.EarlyCDT®-Lungis being used in the largest ever randomised trial for the early detec3on of lung cancer using biomarkers, the Na3onal Health Service (NHS) Scotland ECLS study of

12,210 high-risk smokers.EarlyCDT®-Liverlaunched in May 2018 and further tests are in development.

Oncimmune, headquartered in NoLngham, United Kingdom with tes3ng facili3es in the US, joined AIM in May 2016 under the ticker ONC.L. For more information, visitwww.oncimmune.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please [e-mail] visitwww.rns.com.

END

MSCRFMBTMBJTBBP